These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21434476)

  • 1. Advances in the treatment of non-Hodgkin lymphoma: interleukin-2 fusion toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology. December 4-7, 2004, San Diego, California.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 2):1-5; discussion 6-7. PubMed ID: 21434476
    [No Abstract]   [Full Text] [Related]  

  • 2. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
    Clin Lymphoma; 2003 Dec; 4(3):141-8. PubMed ID: 14715094
    [No Abstract]   [Full Text] [Related]  

  • 4. Denileukin diftitox and vision loss.
    Ruddle JB; Prince HM
    Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
    Foss FM
    Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
    Meneghetti CM; LeMaistre CF
    Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New advances in the management of cutaneous T-cell lymphoma.
    Young SK
    Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
    [No Abstract]   [Full Text] [Related]  

  • 9. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
    Park M; Liu GT; Piltz-Seymour J; Wisda CL; Rook AH; Junkins-Hopkins JM; Nasta SD; Kim EJ
    Leuk Lymphoma; 2007 Apr; 48(4):808-11. PubMed ID: 17454642
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
    Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
    Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 12. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
    Carretero-Margolis CD; Fivenson DP
    J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diphtheria toxin fusion proteins.
    Foss FM; Saleh MN; Krueger JG; Nichols JC; Murphy JR
    Curr Top Microbiol Immunol; 1998; 234():63-81. PubMed ID: 9670613
    [No Abstract]   [Full Text] [Related]  

  • 15. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukins in the treatment of mycosis fungoides.
    Gerami P; Guitart J; Rosen S; Kuzel TM
    G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
    Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
    Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
    Cohen R; Jaffe ES; Stetler-Stevenson MA; Sausville EA; DeNigris EC; Woodworth T; Foss FM
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):229-33. PubMed ID: 7834123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
    McCann S; Akilov OE; Geskin L
    Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.